Generation Patient is pleased to announce our participation in an amicus brief advocating for patients living with narcolepsy, whose access to innovative treatments is at risk due to pharmaceutical monopolies. Our organization is dedicated to championing patients' rights and promoting equitable access to cutting-edge therapies.
The amicus brief supports the FDA's decision to approve Lumryz, a once-a-night medication for narcolepsy that offers clear clinical benefits, as a competitor to Jazz Pharmaceuticals' twice-nightly treatment. The FDA approved both drugs under the Orphan Drug Act, which encourages innovation for conditions affecting smaller patient populations by granting exclusivity for marketing and sales. Jazz Pharmaceuticals has taken legal action against the FDA, alleging that the agency's approval of Lumryz was "unlawful” and violates their exclusivity, but as an organization, we feel that such innovative progress should be celebrated. The amicus brief carefully outlines the unique advantages of Lumryz, particularly the substantial benefit of a single-dose medication for narcolepsy.